Bellco, an Italian company with more than 40 years’ experience, was one of the pioneers in the history of haemodialysis. Bellco operated worldwide, offering systems for the treatment of renal failure, multiple organ failure, sepsis and cardiac decompensation. Its mission was to satisfy the needs of patients and experts through innovation, research and the development of advanced and personalized therapies for nephrology, intensive care and cardiology patients.
Bellco was acquired by Medtronic in February 2016.
Bellco was acquired by Medtronic in February 2016.
Investors 1
| Date | Name | Website |
| - | Amadeus Ca... | amadeuscap... |
Mentions in press and media 3
| Date | Title | Description |
| 24.05.2013 | Blood purification device for ICU patients seeks to treat root cause of sepsis | Although cytokine are proteins that help stimulate and regulate the immune system, an excessive amount can be harmful and lead to organ failure. The target patient population is 65 years old and older since they are most vulnerable and have... |
| 22.02.2013 | Bellco Receives Investment from Amadeus Capital Partners | Bellco, a Mirandola, Italy-based developer of equipment for haemo-dialysis used in kidney disease, received an investment from Amadeus Capital Partners. The amount of the transaction was not disclosed. Amadeus Capital Partners, which joined... |
| - | Blood purification device for ICU patients seeks to treat root cause of sepsis | Medical device company CytoSorbents (OTC: CTSO) has developed a filtration system for the blood to treat the root cause of sepsis for some of the most vulnerable patients in a hospital — those in the intensive care unit. Its device uses pol... |